Cabaletta Bio, Inc.
Late-stage cell-therapy biotech developing rese-cel as a one-time immune-reset approach across autoimmune diseases.
Autoimmune disease · Autologous CD19 CAR-T cell therapy · Registrational / late clinical
Late-stage cell-therapy biotech developing rese-cel as a one-time immune-reset approach across autoimmune diseases.
Autoimmune disease · Autologous CD19 CAR-T cell therapy · Registrational / late clinical